Lenz Therapeutics sells $80 million in common stock in block trade

Lenz Therapeutics (LENZ) recently secured $80 million through a block trade of 1.75 million shares at $45.75, bolstering its financial position. This capital raise coincides with the U.S. launch of its VIZZ presbyopia treatment and positive analyst sentiment, including H.C. Wainwright raising its price target to $56 and naming LENZ a top pick for H2 2025. With $209.6 million in cash expected to fund operations to positive cash flow post-launch and an LNZ100 FDA decision due by August 2025, the company is advancing key commercial and pipeline initiatives.

Analysis

Stock market today: Nasdaq closes above 23,000 for first time as tech rebounds Lenz Therapeutics, Inc. (NASDAQ:LENZ) announced it sold 1,748,634 shares of its common stock at $45.75 per share for gross proceeds of approximately $80 million in a block trade to a single investor. The transaction was completed Tuesday under the company’s "at the market" Sales Agreement with TD Securities (USA) LLC, which was originally dated April 4, 2025. The sale was conducted in accordance with the terms of the previously disclosed Sales Agreement. Lenz Therapeutics is incorporated in Delaware and is headquartered in Solana Beach, California. This information is based on a statement in a press release and a filing with the Securities and Exchange Commission. In other recent news, LENZ Therapeutics has launched its presbyopia treatment, VIZZ (aceclidine ophthalmic solution) 1.44%, in the United States. Professional samples are now being distributed to eye care professionals, with consumer shipments set to begin in October through an ePharmacy partner. The FDA’s approval of VIZZ marks it as the first aceclidine-based eye drop treatment for presbyopia. H.C. Wainwright has raised its price target for LENZ Therapeutics to $56 from $48, maintaining a Buy rating on the stock. The firm has also named LENZ as one of its top picks for the second half of 2025. Additionally, LENZ reported a second-quarter loss of $0.53 per share, while confirming the FDA review of its New Drug Application for LNZ100 is on track for a decision by August 8, 2025. The company has completed hiring and training an 88-member sales force in preparation for potential commercialization. LENZ ended the quarter with $209.6 million in cash, which it anticipates will support operations through to achieving positive cash flow post-launch. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in LENZ right now? First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens, both up over 60%+ each in Q2 of 2025 alone. Is LENZ one of them? Lenz Therapeutics (LENZ) significantly strengthened its balance sheet by executing a block trade, selling 1,748,634 shares at $45.75 per share, generating approximately $80 million in gross proceeds. This capital infusion supports the immediate commercialization efforts for VIZZ, its newly launched presbyopia treatment now available for professional sampling, with consumer shipments slated for October. The company's $209.6 million cash reserve is projected to sustain operations until achieving positive cash flow post-launch. The launch of VIZZ marks a significant milestone, introducing the first aceclidine-based eye drop for presbyopia to the U.S. market. Concurrently, LENZ is progressing with its LNZ100 New Drug Application, with an FDA decision anticipated by August 8, 2025. These dual advancements highlight both immediate revenue potential and future pipeline catalysts, supported by a fully trained 88-member sales force. Analyst sentiment remains strongly positive, with H.C. Wainwright increasing its price target to $56 from $48 and reaffirming a Buy rating, designating LENZ as a top pick for H2 2025. This upgraded outlook, coupled with the successful capital raise and product launch, underscores a bullish market perception despite a reported Q2 loss of $0.53 per share.

Key Decisions for Investors

• Investors should closely track VIZZ's commercial launch metrics and consumer adoption, as these will be critical indicators of revenue generation and the company's path to positive cash flow.
• Evaluate the impact of the upcoming August 8, 2025 FDA decision for LNZ100, which represents a significant near-term catalyst for the company's pipeline and future valuation.
• Consider the bolstered financial position from the $80 million block trade and $209.6 million cash reserves, assessing its sufficiency to support operations through to positive cash flow as guided by management.
• Given the strongly positive analyst sentiment, including H.C. Wainwright's raised price target and "top pick" designation, investors may consider the stock's potential for increased institutional interest and further upside.